Literature DB >> 17453963

Immune reconstitution after unrelated cord blood transplantation.

P Szabolcs1, D Niedzwiecki.   

Abstract

Over the past years unrelated cord blood transplant (UCBT) has emerged as an effective alternative to unrelated donor blood and marrow transplantation. However, despite several advantages, its success is limited by the high incidence of opportunistic infections (OI), most of which are viral. Infection-related mortality is the primary cause of death after UCBT with most deaths occurring in the first 3-6 months post transplant. For several months, until recovery of the thymus is restored to support de novo T cell generation, protective antiviral immunity depends on the activity of post-thymic T cells infused within the cord blood (CB) grafts. However, almost all CB T cells are antigen inexperienced (naïve) lymphocytes that have been functionally altered by placental factors to protect pregnancy. CB T cells need to undergo in vivo priming, Th1/Tc1 maturation, and peripheral expansion before they can afford immunologic protection. This article provides an overview of what is currently known regarding the reconstitution of adaptive immunity following UCBT including our own data from prospective analyses of pediatric cohorts. Remarkable immunophenotypic changes are notable already in the first 2-3 weeks post-UCBT. These changes result from apparent 'homeostatic' peripheral T cell expansion in the lymphopenic environment. While we can identify patient- and graft-specific predictive factors, the concordant emergence of T cell subsets displaying the phenotype of Th1/Tc1 cytotoxic effector cells can be statistically linked to those UCBT recipients who will subsequently develop viral and other opportunistic infections. Antigen presenting dendritic cell reconstitution may also reflect alterations in immunocompetence due to OI and/or GVHD.

Entities:  

Mesh:

Year:  2007        PMID: 17453963      PMCID: PMC2203410          DOI: 10.1080/14653240701231014

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  52 in total

1.  Homeostatic control of T-cell generation in neonates.

Authors:  Stefan O Schönland; Julia K Zimmer; Consuelo M Lopez-Benitez; Thomas Widmann; Kirk D Ramin; Jörg J Goronzy; Cornelia M Weyand
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

2.  Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood.

Authors:  Paul Szabolcs; Kyung-Duk Park; Melissa Reese; Luciana Marti; Gloria Broadwater; Joanne Kurtzberg
Journal:  Exp Hematol       Date:  2003-08       Impact factor: 3.084

3.  Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing.

Authors:  C L Mackall; C V Bare; L A Granger; S O Sharrow; J A Titus; R E Gress
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

Review 4.  Immunological reconstitution following bone marrow transplantation.

Authors:  R Parkman; K I Weinberg
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

5.  Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method.

Authors:  Paul Szabolcs; Kyung-Duk Park; Melissa Reese; Luciana Marti; Gloria Broadwater; Joanne Kurtzberg
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

6.  The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production.

Authors:  J Szekeres-Bartho; Z Faust; P Varga; L Szereday; K Kelemen
Journal:  Am J Reprod Immunol       Date:  1996-04       Impact factor: 3.886

7.  Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation.

Authors:  P Han; G Hodge; C Story; X Xu
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

8.  The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation.

Authors:  J Kurtzberg; M Graham; J Casey; J Olson; C E Stevens; P Rubinstein
Journal:  Blood Cells       Date:  1994

9.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

10.  Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10.

Authors:  I Roth; D B Corry; R M Locksley; J S Abrams; M J Litton; S J Fisher
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  44 in total

1.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.

Authors:  Craig C Davis; Luciana C Marti; Gregory D Sempowski; Durairaj A Jeyaraj; Paul Szabolcs
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

3.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

4.  Ex vivo expansion and Th1/Tc1 maturation of umbilical cord blood T cells by CD3/CD28 costimulation.

Authors:  Melissa A Mazur; Craig C Davis; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

5.  Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation.

Authors:  L Farnault; J Gertner-Dardenne; F Gondois-Rey; G Michel; H Chambost; I Hirsch; D Olive
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

Review 6.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

7.  Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.

Authors:  Allistair A Abraham; Tami D John; Michael D Keller; C Russell N Cruz; Baheyeldin Salem; Lauren Roesch; Hao Liu; Fahmida Hoq; Bambi J Grilley; Adrian P Gee; Hema Dave; David A Jacobsohn; Robert A Krance; Elizabeth J Shpall; Caridad A Martinez; Patrick J Hanley; Catherine M Bollard
Journal:  Blood Adv       Date:  2019-07-23

8.  Umbilical cord blood transplantation.

Authors:  Hong Hoe Koo; Hyo Seop Ahn
Journal:  Korean J Pediatr       Date:  2012-07-17

9.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

10.  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.

Authors:  Jill C Beck; John E Wagner; Todd E DeFor; Claudio G Brunstein; Mark R Schleiss; Jo-Anne Young; Daniel H Weisdorf; Sarah Cooley; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.